Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-20 | Sep-30-20 | Jun-05-20 | Mar-31-20 | Dec-31-19 | Sep-30-19 | Jun-30-19 | Jun-05-19 |
| | 10-K | 10-Q | 8-K | 10-Q | 10-K | 10-Q | 10-Q | 8-K |
| Revenues: |
| Clinical Research | 797.5 | 732.1 | | 726.1 | 725.1 | 719.0 | 702.2 | |
| Data Solutions | 75.9 | 64.2 | | 57.6 | 75.1 | 61.7 | 61.1 | |
| Total Americas | | 540.7 | | 534.4 | | 541.0 | 531.8 | |
| Total revenues | 873.5 | 796.3 | 729.9 | 783.7 | 800.2 | 780.7 | 763.3 | 763.3 |
| Revenue growth [+] | 9.1% | 2.0% | -4.4% | 8.5% | 9.7% | 8.8% | 5.6% | |
| Clinical Research | 10.0% | 1.8% | | 8.9% | 10.6% | 9.4% | 5.6% | |
| Data Solutions | 1.1% | 4.0% | | 3.9% | 1.5% | 1.8% | 5.1% | |
| Total Americas | | -0.1% | | 4.6% | | 7.1% | 5.2% | |
| Cost of goods sold [+] | 622.0 | 523.4 | 395.3 | 581.3 | 565.8 | 559.8 | 547.3 | 386.2 |
| Reimbursable costs | | | 148.3 | | | | | 161.1 |
| Gross profit | 251.5 | 272.9 | 334.6 | 202.4 | 234.5 | 220.9 | 216.0 | 377.1 |
| Gross margin | 28.8% | 34.3% | 45.8% | 25.8% | 29.3% | 28.3% | 28.3% | 49.4% |
| Selling, general and administrative [+] | 120.7 | 115.4 | 110.0 | 107.0 | 103.5 | 95.5 | 98.8 | 98.8 |
| General and administrative | 120.7 | | | | 103.5 | | | |
| Equity in earnings | | | | | | | | |
| Other operating expenses | | | 148.3 | | | | | 161.1 |
| EBITDA [+] | 130.8 | 157.5 | 76.3 | 95.4 | 131.0 | 125.3 | 117.2 | 117.2 |
| EBITDA growth | -0.2% | 25.7% | -34.9% | -10.3% | 4.8% | 86.7% | 14.4% | |
| EBITDA margin | 15.0% | 19.8% | 10.5% | 12.2% | 16.4% | 16.1% | 15.3% | 15.3% |
| Depreciation | 14.5 | -23.9 | 32.5 | 13.2 | 12.2 | 12.2 | 11.5 | 28.6 |
| EBITA | 116.3 | 181.4 | 43.8 | 82.3 | 118.8 | 113.1 | 105.7 | 88.6 |
| EBITA margin | 13.3% | 22.8% | 6.0% | 10.5% | 14.8% | 14.5% | 13.8% | 11.6% |
| Amortization of intangibles | 19.1 | 57.2 | | 19.1 | 17.2 | 17.1 | 17.1 | |
| EBIT [+] | 97.2 | 124.2 | 43.8 | 63.2 | 101.6 | 96.0 | 88.6 | 88.6 |
| EBIT growth | -4.3% | 29.3% | -50.5% | -19.9% | 4.8% | 147.3% | 19.9% | |
| EBIT margin | 11.1% | 15.6% | 6.0% | 8.1% | 12.7% | 12.3% | 11.6% | 11.6% |
| Non-recurring items [+] | 0.1 | 0.0 | 0.2 | 0.0 | 0.2 | 0.3 | 0.6 | 0.6 |
| Loss (gain) on sale of assets | 0.1 | 0.0 | 0.2 | 0.0 | 0.2 | 0.3 | 0.6 | 0.6 |
| Interest expense | 7.0 | 10.7 | 11.9 | 13.5 | 14.2 | 13.0 | 12.5 | 12.5 |
| Interest expense | 7.0 | 10.7 | 11.9 | 13.5 | 14.2 | 13.0 | 12.5 | 12.5 |
| Other income (expense), net [+] | -13.9 | -9.1 | -10.7 | 7.8 | -6.0 | 3.6 | -9.7 | -9.7 |
| Gain (loss) on foreign currency transactions | -13.5 | -9.1 | -10.8 | 7.8 | -4.1 | 5.4 | -9.7 | -9.7 |
| Other | | 0.0 | | 0.0 | 0.2 | 0.0 | 0.0 | |
| Pre-tax income | 76.2 | 104.3 | 21.0 | 57.5 | 81.3 | 86.4 | 65.9 | 65.9 |
| Income taxes | 24.9 | 13.1 | 7.1 | 16.9 | 6.5 | 3.4 | 24.8 | 24.8 |
| Tax rate | 32.7% | 12.5% | 33.9% | 29.3% | 8.0% | 3.9% | 37.7% | 37.7% |
| Minority interest | | | | | | | -0.1 | 0.1 |
| Net income | 51.3 | 91.3 | 13.9 | 40.7 | 74.8 | 83.0 | 41.1 | 41.1 |
| Net margin | 5.9% | 11.5% | 1.9% | 5.2% | 9.3% | 10.6% | 5.4% | 5.4% |
| |
| Basic EPS [+] | $0.81 | $1.44 | $0.22 | $0.65 | $1.16 | $1.28 | $0.63 | $0.63 |
| Growth | -30.2% | 12.2% | -65.1% | -4.5% | 4.1% | 5408.6% | -4.2% | |
| Diluted EPS [+] | $0.79 | $1.41 | $0.22 | $0.63 | $1.13 | $1.25 | $0.62 | $0.62 |
| Growth | -30.2% | 12.2% | -65.1% | -4.2% | 5.2% | 5476.9% | -3.0% | |
| |
| |
| Shares outstanding (basic) [+] | 63.4 | 63.4 | 63.2 | 62.9 | 64.5 | 64.8 | 65.3 | 65.3 |
| Growth | -1.8% | -2.0% | -3.3% | -3.5% | 0.6% | 0.8% | 2.3% | |
| Shares outstanding (diluted) [+] | 64.8 | 64.9 | 64.5 | 64.3 | 66.0 | 66.2 | 66.8 | 66.8 |
| Growth | -1.9% | -2.0% | -3.5% | -3.8% | -0.5% | -0.4% | 1.0% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|